Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CLNN NASDAQ:CRGX NASDAQ:ENGN NASDAQ:GNFT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLNNClene$5.32-1.7%$4.05$2.28▼$6.90$54.05M0.55104,716 shs33,033 shsCRGXCARGO Therapeutics$4.47$4.45$3.00▼$25.45$216.17M0.31.73 million shsN/AENGNenGene$4.62-2.7%$3.76$2.65▼$11.00$242.75M-0.4168,803 shs24,873 shsGNFTGENFIT$3.89-4.2%$3.91$2.55▼$6.42$203.11M1.143,790 shs1,234 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLNNClene-1.66%-6.01%+52.44%+70.51%-5.84%CRGXCARGO Therapeutics0.00%0.00%0.00%+5.42%-73.66%ENGNenGene-2.74%+6.94%+32.00%+19.38%-29.14%GNFTGENFIT-3.45%-9.85%-0.10%-11.16%-7.66%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCLNNClene3.2748 of 5 stars3.64.00.00.02.72.50.6CRGXCARGO Therapeutics2.0037 of 5 stars2.90.00.00.02.01.71.3ENGNenGene3.0531 of 5 stars3.55.00.00.01.12.50.6GNFTGENFIT1.9124 of 5 stars3.53.00.00.02.80.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLNNClene 3.17Buy$33.00520.30% UpsideCRGXCARGO Therapeutics 1.86Reduce$15.40244.52% UpsideENGNenGene 3.00Buy$23.29404.02% UpsideGNFTGENFIT 3.00Buy$9.00131.30% UpsideCurrent Analyst Ratings BreakdownLatest CLNN, ENGN, GNFT, and CRGX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/21/2025CLNNCleneD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$23.008/19/2025GNFTGENFITHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$9.008/18/2025CLNNCleneCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$83.00 ➝ $48.008/14/2025CLNNCleneD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$23.007/18/2025CLNNCleneD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$23.007/8/2025CRGXCARGO TherapeuticsJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetHold ➝ Hold$3.70 ➝ $5.006/30/2025CLNNCleneD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$23.00(Data available from 8/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLNNClene$340K156.31N/AN/A($0.86) per share-6.19CRGXCARGO TherapeuticsN/AN/AN/AN/A$4.91 per shareN/AENGNenGeneN/AN/AN/AN/A$5.35 per shareN/AGNFTGENFIT$76.77M2.53$0.07 per share58.07$1.50 per share2.59Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLNNClene-$39.40M-$3.76N/AN/AN/A-10,386.36%N/A-125.49%11/12/2025 (Estimated)CRGXCARGO Therapeutics-$167.50M-$4.64N/AN/AN/AN/A-43.21%-37.26%11/11/2025 (Estimated)ENGNenGene-$55.14M-$1.65N/AN/AN/AN/A-32.60%-28.26%9/10/2025 (Estimated)GNFTGENFIT$1.63MN/A0.00N/AN/AN/AN/AN/A9/22/2025 (Estimated)Latest CLNN, ENGN, GNFT, and CRGX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails9/10/2025Q3 2025ENGNenGene-$0.5084N/AN/AN/AN/AN/A8/14/2025Q2 2025CLNNClene-$0.49-$0.78-$0.29-$0.78$0.06 million$0.03 million6/10/2025Q2 2025ENGNenGene-$0.4768-$0.51-$0.0332-$0.51N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCLNNCleneN/AN/AN/AN/AN/ACRGXCARGO TherapeuticsN/AN/AN/AN/AN/AENGNenGeneN/AN/AN/AN/AN/AGNFTGENFITN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLNNCleneN/A1.581.57CRGXCARGO TherapeuticsN/A12.3712.37ENGNenGene0.0912.6612.66GNFTGENFIT0.081.231.23Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLNNClene23.28%CRGXCARGO Therapeutics93.16%ENGNenGene64.16%GNFTGENFIT2.24%Insider OwnershipCompanyInsider OwnershipCLNNClene35.30%CRGXCARGO Therapeutics2.92%ENGNenGene10.40%GNFTGENFIT4.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCLNNClene1009.99 million6.46 millionOptionableCRGXCARGO Therapeutics11648.36 million46.95 millionN/AENGNenGene3151.10 million45.79 millionN/AGNFTGENFIT12050.00 million47.90 millionNot OptionableCLNN, ENGN, GNFT, and CRGX HeadlinesRecent News About These CompaniesMASH drug developers rise as FDA accepts lenient trial requirementAugust 27 at 5:13 PM | msn.comFY2025 Earnings Forecast for GENFIT Issued By HC WainwrightAugust 23, 2025 | marketbeat.comFY2025 Earnings Estimate for GENFIT Issued By HC WainwrightAugust 22, 2025 | americanbankingnews.comGENFIT's (GNFT) "Buy" Rating Reiterated at HC WainwrightAugust 21, 2025 | marketbeat.comHC Wainwright Initiates Coverage on GENFIT (NASDAQ:GNFT)August 21, 2025 | americanbankingnews.comGENFIT (NASDAQ:GNFT) Stock Price Down 3.4% - Time to Sell?August 1, 2025 | marketbeat.comKepler Capital Maintained a Buy Rating on Genfit (GNFT)July 28, 2025 | msn.comGenfit: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial - The Manila TimesJuly 9, 2025 | manilatimes.netMGenfit: Half-Year Report of Liquidity Contract with Crédit Industriel et CommercialJuly 8, 2025 | globenewswire.comGENFIT: June 17, 2025 Combined Shareholders Meeting ResultsJune 17, 2025 | globenewswire.comGENFIT S.A.: GENFIT Reports First Quarter 2025 Financial InformationMay 23, 2025 | finanznachrichten.deGENFIT Reports First Quarter 2025 Financial InformationMay 22, 2025 | globenewswire.comGENFIT to receive a €26.5 million milestone payment following the approval of pricing and reimbursement of Ipsen's Iqirvo® in ItalyMay 20, 2025 | globenewswire.comGENFIT S.A.: Publication of the 2025 Extra-Financial Performance Report (fiscal year 2024)May 15, 2025 | finanznachrichten.deGENFIT: Publication of the 2025 Extra-Financial Performance Report (fiscal year 2024)May 14, 2025 | globenewswire.comGenfit: Iqirvo's Success Can't Outweigh ACLF Pipeline RisksMay 12, 2025 | seekingalpha.comGENFIT Annual Combined General Meeting of June 17, 2025 — Availability of Preparatory DocumentsMay 7, 2025 | globenewswire.comGENFIT to Present Latest ACLF Research at EASL Congress 2025May 5, 2025 | globenewswire.comGENFIT Announces Publication of the 2024 Universal Registration Document and the 2024 Annual Report on Form 20-FApril 29, 2025 | globenewswire.comGENFIT: positive late-breaking Phase 2 data for elafibranor in Primary Sclerosing Cholangitis (PSC) to be presented by Ipsen at EASL Congress 2025April 28, 2025 | globenewswire.comGENFIT S.A.: GENFIT Reports Full-Year 2024 Financial Results and Provides Corporate UpdateApril 25, 2025 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCLNN, ENGN, GNFT, and CRGX Company DescriptionsClene NASDAQ:CLNN$5.32 -0.09 (-1.66%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$5.30 -0.02 (-0.38%) As of 08/29/2025 06:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company also develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.CARGO Therapeutics NASDAQ:CRGX$4.47 0.00 (0.00%) As of 08/19/2025CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies. It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets. The company was formerly known as Syncopation Life Sciences, Inc. and changed its name to CARGO Therapeutics, Inc. in September 2022. CARGO Therapeutics, Inc. was incorporated in 2019 and is headquartered in San Mateo, California.enGene NASDAQ:ENGN$4.62 -0.13 (-2.74%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$4.74 +0.12 (+2.68%) As of 08/29/2025 04:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.GENFIT NASDAQ:GNFT$3.87 -0.19 (-4.68%) As of 08/29/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor NVIDIA Stock Could Pull Back in September, But Don’t Bet on It 3 Reasons Gartner Could Be the Best Buy of Q3 NIO Just Got Its Second Upgrade of the Month, and It’s Big Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
